Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial

Published:2023-01 Issue:1 Volume:8 Page:43-55
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Sandborn William J,Panés Julian,Danese Silvio,Sharafali Zaineb,Hassanali Azra,Jacob-Moffatt Rhian,Eden Christopher,Daperno Marco,Valentine John F,Laharie David,Baía Carolina,Atreya Raja,Panaccione Remo,Rydzewska Grazyna,Aguilar Humberto,Vermeire Séverine

Funder

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference21 articles.

1. A review of the therapeutic management of Crohn's disease;Kumar;Therap Adv Gastroenterol,2022

2. Long-term evolution of disease behavior of Crohn's disease;Cosnes;Inflamm Bowel Dis,2002

3. Inflammatory bowel disease course in Crohn's disease: is the natural history changing?;Golovics;World J Gastroenterol,2014

4. Review article: emerging drug therapies in inflammatory bowel disease;Grossberg;Aliment Pharmacol Ther,2022

5. The role of integrins in the pathogenesis of inflammatory bowel disease: approved and investigational anti-integrin therapies;Dotan;Med Res Rev,2020

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis;PeerJ;2024-08-23

2. Dysbiosis-associated gut bacteriumRuminococcus gnavusvaries at the strain level in ability to utilize key mucin component sialic acid;2024-08-02

3. T cell trafficking in human chronic inflammatory diseases;iScience;2024-08

4. Cryo-EM structure of I domain-containing integrin αEβ7;Biochemical and Biophysical Research Communications;2024-08

5. FORWARD: A Learning Framework for Logical Network Perturbations to Prioritize Targets for Drug Development;2024-07-19